Abeona Therapeutics(ABEO) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Abeona Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates FDA accepts BLA resubmission of pz-cel in recessive dystrophic epidermolysis bullosa and sets PDUFA target action date of April 29, 2025 Company makes significant progress toward potential commercialization of pz-cel in 2025; Builds momentum with payor discussions and target treatment centers CLEVELAND, November 14, 2024 – Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the ...